1. Cancers (Basel). 2019 Oct 8;11(10):1504. doi: 10.3390/cancers11101504.

Clinical Practice Use of Liquid Biopsy to Identify RAS/BRAF Mutations in 
Patients with Metastatic Colorectal Cancer (mCRC): A Single Institution 
Experience.

Vitiello PP(1), De Falco V(2), Giunta EF(3), Ciardiello D(4), Cardone C(5), 
Vitale P(6), Zanaletti N(7), Borrelli C(8), Poliero L(9), Terminiello M(10), 
Arrichiello G(11), Caputo V(12), Famiglietti V(13), Mattera Iacono V(14), 
Marrone F(15), Di Liello A(16), Martini G(17)(18), Napolitano S(19)(20), 
Caraglia M(21), Lombardi A(22), Franco R(23), De Vita F(24), Morgillo F(25), 
Troiani T(26), Ciardiello F(27), Martinelli E(28).

Author information:
(1)Department of Precision Medicine, Università della Campania "Luigi 
Vanvitelli", 80131 Napoli, Italy. pietropaolo.vitiello@gmail.com.
(2)Department of Precision Medicine, Università della Campania "Luigi 
Vanvitelli", 80131 Napoli, Italy. vincenzodefalc@gmail.com.
(3)Department of Precision Medicine, Università della Campania "Luigi 
Vanvitelli", 80131 Napoli, Italy. emiliofrancescogiunta@gmail.com.
(4)Department of Precision Medicine, Università della Campania "Luigi 
Vanvitelli", 80131 Napoli, Italy. davideciardiello@yahoo.it.
(5)Department of Precision Medicine, Università della Campania "Luigi 
Vanvitelli", 80131 Napoli, Italy. claudia.cardone88@gmail.com.
(6)Department of Precision Medicine, Università della Campania "Luigi 
Vanvitelli", 80131 Napoli, Italy. vitale.pasquale.89@gmail.com.
(7)Department of Precision Medicine, Università della Campania "Luigi 
Vanvitelli", 80131 Napoli, Italy. nicolettazanaletti@gmail.com.
(8)Department of Precision Medicine, Università della Campania "Luigi 
Vanvitelli", 80131 Napoli, Italy. carola.bor@libero.it.
(9)Department of Precision Medicine, Università della Campania "Luigi 
Vanvitelli", 80131 Napoli, Italy. luca.poliero@libero.it.
(10)Department of Precision Medicine, Università della Campania "Luigi 
Vanvitelli", 80131 Napoli, Italy. marinella.terminiello@gmail.com.
(11)Department of Precision Medicine, Università della Campania "Luigi 
Vanvitelli", 80131 Napoli, Italy. gluca.arrichiello@gmail.com.
(12)Department of Precision Medicine, Università della Campania "Luigi 
Vanvitelli", 80131 Napoli, Italy. vincenza.caputo.92@gmail.com.
(13)Department of Precision Medicine, Università della Campania "Luigi 
Vanvitelli", 80131 Napoli, Italy. vincenzo.famiglietti@yahoo.it.
(14)Department of Precision Medicine, Università della Campania "Luigi 
Vanvitelli", 80131 Napoli, Italy. vmatteraiacono@gmail.com.
(15)Department of Precision Medicine, Università della Campania "Luigi 
Vanvitelli", 80131 Napoli, Italy. francesca.marrone@email.it.
(16)Department of Precision Medicine, Università della Campania "Luigi 
Vanvitelli", 80131 Napoli, Italy. dilielloalessandra@gmail.com.
(17)Department of Precision Medicine, Università della Campania "Luigi 
Vanvitelli", 80131 Napoli, Italy. giulia.mart14@gmail.com.
(18)Centro Cellex, Vall D'Hebron Institute of Oncology (VHIO), 08035 Barcelona, 
Spain. giulia.mart14@gmail.com.
(19)Department of Precision Medicine, Università della Campania "Luigi 
Vanvitelli", 80131 Napoli, Italy. stenap@fastwebnet.it.
(20)Department of Gastrointestinal Medical Oncology, University of Texas, MD 
Anderson Cancer Center, Houston, TX 77030, USA. stenap@fastwebnet.it.
(21)Department of Experimental Medicine, Università della Campania "Luigi 
Vanvitelli", 80138 Napoli, Italy. michele.caraglia@unicampania.it.
(22)Department of Experimental Medicine, Università della Campania "Luigi 
Vanvitelli", 80138 Napoli, Italy. angela.lombardi@unicampania.it.
(23)Department of Mental and Physical Health and Preventive Medicine, Pathology 
Unit, Università della Campania "Luigi Vanvitelli", 80138 Napoli, Italy. 
renato.franco@unicampania.it.
(24)Department of Precision Medicine, Università della Campania "Luigi 
Vanvitelli", 80131 Napoli, Italy. ferdinando.devita@unicampania.it.
(25)Department of Precision Medicine, Università della Campania "Luigi 
Vanvitelli", 80131 Napoli, Italy. floriana.morgillo@unicampania.it.
(26)Department of Precision Medicine, Università della Campania "Luigi 
Vanvitelli", 80131 Napoli, Italy. teresa.troiani@unicampania.it.
(27)Department of Precision Medicine, Università della Campania "Luigi 
Vanvitelli", 80131 Napoli, Italy.
(28)Department of Precision Medicine, Università della Campania "Luigi 
Vanvitelli", 80131 Napoli, Italy. erika.martinelli@unicampania.it.

Tumor heterogeneity represents a possible cause of error in detecting predictive 
genetic alterations on tumor tissue and can be overcome by testing alterations 
in circulating tumor DNA (ctDNA) using liquid biopsy. We assessed 72 consecutive 
patients with a diagnosis of metastatic colorectal cancer (mCRC) using Idylla™ 
Biocartis, a fully automated platform that evaluates the most frequent mutations 
of KRAS, NRAS and BRAF genes. We correlated the results of liquid biopsy and 
standard tissue-based next generation sequencing (NGS) analyses to patient 
clinical features. The overall agreement was 81.94%. Concordance was 85.71% and 
96.15% in treatment-naïve patients and in the patient subgroup with liver 
metastases, respectively. In liver metastases positive, treatment-naïve 
patients, sensitivity, specificity and positive predictive value (PPV) were 
92.31%, 100% and 100%, respectively. Circulating mutational fraction (CMF) was 
significantly higher in patients with liver metastases and high carcinoembryonic 
antigen (CEA) levels. In a subgroup of patients pre-treated with anti-Epidermal 
Growth Factor Receptor (EGFR) agents, emerging KRAS mutations were evidenced in 
33% of cases. Testing RAS/BRAF mutations on plasma using the Idylla™ Biocartis 
platform is feasible and reliable in mCRC patients in clinical practice.

DOI: 10.3390/cancers11101504
PMCID: PMC6827157
PMID: 31597339

Conflict of interest statement: P.P.V.: consultancy for Biocartis. E.M.: 
advisory board for Amgen, Bayer, Merck, Roche, Sanofi, Servier and expert 
opinion for ESMO (European Society of Medical Oncology). T.T.: advisory board 
for Amgen, Bayer, Merck, Novartis, Roche, Sanofi. F.M.: advisory board for 
Lilly, MSD. F.D.V.: advisory board for Amgen, Lilly, Roche, Celgene. F.C.: 
advisory board for Merck, Roche, Amgen, Bayer, Servier, Symphogen,Pfizer and 
research funding from Roche, Merck, Amgen, Bayer, Ipsen. V.D.F., E.F.G., D.C., 
C.C., C.B., L.P., M.T., G.A., V.C., A.D.L., V.F., V.M.I., F.M., G.M., S.N., 
R.F., A.L., M.C. declare no competing conflict of interest regarding the 
following manuscript. The funders had no role in the design of the study; in the 
collection, analyses, or interpretation of data; in the writing of the 
manuscript, or in the decision to publish the results.